Prodrugs of proton pump inhibitors
US6093734A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 10, 1998 |
| Grant date | Jul 25, 2000 |
| Priority date | — |
| Expiry date | Aug 10, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65583
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a Mannich base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.